420 related articles for article (PubMed ID: 22760023)
1. Tumor angiogenesis and anti-angiogenic therapy.
Kubota Y
Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
3. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
4. Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
Parmar D; Apte M
Eur J Pharmacol; 2021 May; 899():174021. PubMed ID: 33741382
[TBL] [Abstract][Full Text] [Related]
5. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
6. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
Fischer C; Jonckx B; Mazzone M; Zacchigna S; Loges S; Pattarini L; Chorianopoulos E; Liesenborghs L; Koch M; De Mol M; Autiero M; Wyns S; Plaisance S; Moons L; van Rooijen N; Giacca M; Stassen JM; Dewerchin M; Collen D; Carmeliet P
Cell; 2007 Nov; 131(3):463-75. PubMed ID: 17981115
[TBL] [Abstract][Full Text] [Related]
7. Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies.
Darvishi B; Majidzadeh-A K; Ghadirian R; Mosayebzadeh M; Farahmand L
Life Sci; 2019 Jan; 217():34-40. PubMed ID: 30472294
[TBL] [Abstract][Full Text] [Related]
8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
9. The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.
Rocchi L; Caraffi S; Perris R; Mangieri D
Biosci Rep; 2014 Nov; 34(6):e00147. PubMed ID: 25236925
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic alternatives to VEGF blockade.
Khan KA; Bicknell R
Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
[TBL] [Abstract][Full Text] [Related]
11. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Itatani Y; Kawada K; Yamamoto T; Sakai Y
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670046
[TBL] [Abstract][Full Text] [Related]
13. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
14. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
17. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
Niu G; Chen X
Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
20. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]